Abstract
Management of Cutaneous Toxicity Secondary to Targeted Agents in Melanoma
Highlights
Melanoma is the most aggressive skin cancer and its incidence continues to increase worldwide
We describe the case of a patient under treatment with BRAF and MEK inhibitors (BRAFi and MEKi) who presents cutaneous toxicity grade 3, as an adverse effect due to treatment
50% of advanced melanomas have BRAF V600 mutations that result in constitutive activation of the mitogen activated protein kinase (MAPK) pathway
Summary
Melanoma is the most aggressive skin cancer and its incidence continues to increase worldwide. We describe the case of a patient under treatment with BRAF and MEK inhibitors (BRAFi and MEKi) who presents cutaneous toxicity grade 3, as an adverse effect due to treatment. Surgical removal was taken with large edges and inguinal lymphadenectomy with transposition of sartorius muscle and close with drainage Afterwards, she was remitted to Oncology Department and we started nivolumab as adjuvant treatment (240 mg every two weeks). Three weeks later (first treatment cycle completed), she was admitted at the Emergency Room presenting erythematous lesions in lower limbs, fever and cough without expectoration. After the toxicodermia presented by iBRAF and iMEK, it was decided to keep on this treatment, but reduce the dose (vemurafenib 480 mg twice every day and cobimetinib 40 mg daily). The patient presented excellent tolerance and without incidence of new reactions adverse up to three months
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call